Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 29, 2006. The report announces a change to the Board of Directors, specifically the appointment of Dr. Daniel Podolsky as a Non-Executive Director effective July 1, 2006.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance announcement and does not contain financial performance data.
Material Changes
- Board Appointment: Dr. Daniel Podolsky has been appointed as an Independent Non-Executive Director.
- Committee Assignments: Dr. Podolsky and Tom de Swaan have been appointed to the Corporate Responsibility Committee.
- Future Audit Committee Change: Mr. Tom de Swaan is scheduled to succeed Dr. Ronaldo Schmitz as Chairman of the Audit Committee in September 2006.
Management Commentary and Outlook
Sir Christopher Gent, Chairman of GSK, stated that Dr. Podolsky will fulfill standard non-executive responsibilities while also spending time within the research and development organization. His expertise in gastrointestinal disorders and scientific developments is expected to provide valuable insights to the company. The Board has determined that Dr. Podolsky is independent in accordance with the Combined Code on Corporate Governance.
Key Facts for Investor Verification
- Dr. Daniel Podolsky's effective start date as a Non-Executive Director is July 1, 2006.
- Dr. Podolsky brings specific expertise in gastroenterology and innate immunity to the Board.
- Mr. Tom de Swaan will assume the role of Audit Committee Chairman in September 2006.
- This filing contains no financial results; investors should refer to Form 20-F or quarterly reports for financial data.